Please login to the form below

Not currently logged in
Email:
Password:

EC clears AbbVie's oral hepatitis C regimen

Viekirax and Exviera offer competition to Gilead’s Sovaldi
AbbVie-Viekira-Pak-hepatitis-C

The Viekirax/Exviera regimen was approved as Viekira Pak in the US

AbbVie is celebrating the approval of its all-oral hepatitis C treatment in Europe, just a few weeks after the blockbuster-in-waiting was registered in the US.

The approval of Viekirax (ombitasvir/paritaprevir/ritonavir) and Exviera (dasabuvir), which follows a recommendation from the European Medicines Agency (EMA), will allow AbbVie to take its fight with rival Gilead Sciences in the hepatitis C virus (HCV) market onto a second front.

The interferon-free regimen - which is based on three directly-acting antivirals and a boosting agent, was approved by the FDA as Viekira Pak in December as the first major competition to Gilead's Sovaldi (sofosbuvir) and Harvoni (sofosbuvir/ledipasvir) franchise, and has also been given a green light in Canada.

Gilead has already made billions of dollars in revenues from its all-oral HCV therapies, which have largely done away with the need for hard-to-tolerate - and less effective - interferon alfa infections. AbbVie's regimen is expected to be its closest rival in the evolving HCV market.

Viekirax and Exviera have been approved in the EU for use - with or without ribavirin - in patients with genotype 1 chronic HCV, including those with compensated liver cirrhosis, HIV-1 co-infection, patients on opioid substitution therapy and liver transplant recipients. Viekirax has also been approved for use with ribavirin in genotype 4 HCV.

AbbVie chief executive Richard Gonzalez said that Viekirax and Exviera are a "new and effective treatment to cure this serious disease", adding that the company was "committed to working with local governments and healthcare systems to support broad access" to them.

Despite Gilead's lead in the US market AbbVie has already made in-roads into its market share, thanks to a reduced price versus Harvoni that encouraged health insurer Express Scripts to include only Viekira in its formulary at the end of last year.

Since then, it has emerged that Gilead has offered a deal to rival insurer Humana that has secured exclusivity for Harvoni in its formulary in return for an undisclosed discount. Other insurers are likely to be considering this type of approach, although doctors have complained that this type of horse-trading impacts on their treatment decisions.

The move is significant as Gilead has staunchly resisted any discounting for Sovaldi in high-income countries, on the grounds that its drugs are not much more expensive than interferon/ribavirin therapy and a fraction of the cost of a liver transplant.

Article by
Phil Taylor

16th January 2015

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
emotive.

emotive. is an award-winning healthcare communications agency working with leading global and EMEA companies in life sciences including medical device...

Latest intelligence

Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...
fig 1
Pharma social media
Posting frequency is down as companies take a ‘less is more’ approach...
Phillip Lee
The case for a second Brexit referendum: “We need the informed consent of the people”
Dr Phillip Lee MP is fighting to keep the UK in the EMA network - and for a second referendum...

Infographics